Jasper Therapeutics, Inc.
NASDAQ:JSPR
22.74 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 2.052 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.299 | 0.288 | 0.283 | 0.276 | 0.377 | 0.373 | 0.367 | 0.358 | 0.313 | 0.272 | 0.23 | 0.336 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.299 | -0.288 | 1.769 | -0.276 | -0.377 | -0.373 | -0.367 | -0.358 | -0.313 | -0.272 | -0.23 | -0.336 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0.862 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 11.296 | 10.298 | 13.835 | 14.848 | 13.297 | 9.805 | 9.282 | 9.022 | 8.135 | 8.188 | 8.657 | 7.188 | 5.156 | 4.42 | 4.647 | 4.52 | 4.776 | 1.94 |
| General & Administrative Expenses
| 4.697 | 4.774 | 3.89 | 4.514 | 4.53 | 4.142 | 4.465 | 3.686 | 3.828 | 4.59 | 3.425 | 2.891 | 3.262 | 1.834 | 1.311 | 1.488 | 1.236 | 0.765 |
| Selling & Marketing Expenses
| 0 | -0.288 | -0.283 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 4.697 | 4.486 | 3.607 | 4.514 | 4.53 | 4.142 | 4.465 | 3.686 | 3.828 | 4.59 | 3.425 | 2.891 | 3.262 | 1.834 | 1.311 | 1.488 | 1.236 | 0.765 |
| Other Expenses
| 0 | -0.022 | -0.118 | 0.051 | -0.109 | -0.07 | 0.301 | 0 | 0.089 | -0.072 | 0 | 0 | 0.004 | 0.001 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 15.993 | 14.784 | 17.442 | 19.362 | 17.827 | 13.947 | 13.747 | 12.708 | 11.963 | 12.778 | 12.082 | 10.079 | 8.418 | 6.254 | 5.958 | 6.008 | 9.392 | 1.483 |
| Operating Income
| -15.993 | -15.072 | -17.725 | -19.362 | -17.827 | -13.947 | -13.747 | -12.708 | -11.963 | -12.778 | -12.082 | -10.079 | -8.418 | -6.254 | -5.958 | -6.008 | -6.012 | -2.705 |
| Operating Income Ratio
| 0 | 0 | -8.638 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.41 | 1.344 | 1.144 | 0.385 | 0.311 | -0.313 | 0.536 | 0.845 | 1.559 | 10.571 | 3.021 | 6.676 | 0.004 | -3.5 | -4.122 | -4.706 | -3.411 | 1.271 |
| Income Before Tax
| -14.583 | -13.728 | -16.581 | -17.544 | -16.08 | -14.26 | -13.211 | -11.863 | -10.404 | -2.207 | -9.057 | -3.412 | -8.414 | -9.754 | -9.987 | -10.825 | -9.423 | -1.434 |
| Income Before Tax Ratio
| 0 | 0 | -8.08 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0.299 | 0.245 | 1.913 | -1.709 | -1.856 | 1.652 | -0.536 | -1.113 | -1.559 | -10.571 | -9.301 | -0.132 | -0.004 | 7.001 | 4.029 | 4.706 | 0.001 | 1.271 |
| Net Income
| -14.583 | -13.728 | -16.581 | -17.544 | -16.08 | -15.912 | -12.675 | -10.75 | -8.845 | 8.364 | -9.057 | -3.412 | -8.414 | -9.754 | -9.987 | -10.825 | -9.423 | -1.434 |
| Net Income Ratio
| 0 | 0 | -8.08 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.97 | -1.03 | -1.5 | -1.6 | -1.47 | -1.8 | -3.46 | -0.29 | -0.24 | 0.23 | -1.82 | -0.69 | -0.22 | -0.26 | -0.26 | -0.29 | -16.08 | 0 |
| EPS Diluted
| -0.97 | -1.03 | -1.5 | -1.6 | -1.47 | -1.8 | -3.46 | -0.29 | -0.24 | 0.23 | -1.82 | -0.69 | -0.22 | -0.26 | -0.26 | -0.29 | -16.06 | 0 |
| EBITDA
| -15.993 | -14.784 | -17.442 | -19.362 | -17.972 | -12.334 | -13.982 | -13.017 | -13.215 | -23.205 | -18.164 | -9.947 | -8.389 | -2.731 | 4.917 | -6.008 | -3.411 | 1.271 |
| EBITDA Ratio
| 0 | 0 | -8.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |